Studies suggest the use of continuous processes for facilities producing oral solid dosage (OSD) formulations is less labour intensive, more efficient and could lead to more consistent product quality. Investing in CM can also reduce disruptions in the flow of drugs during global risk events, like the COVID-19 pandemic.

In the biologics space, too, there is increased interest in the use of continuous bioprocesses. A recent study predicted that end-to-end continuous manufacturing of monoclonal antibodies (mAbs) could be 20-40 percent more cost effective than batch processes.

But is PCM a viable commercial proposition?
In this session, speakers will draw on their own experiences and strategies implementing continuous manufacturing processes for a range of drug products and drug substances. The panel will also explore the benefits, challenges and opportunities for increasing adoption of CM across the pharmaceutical industry.

Discussion points

  • The economics of CM over batch manufacturing
  • Strategies and approaches for implementing continuous processes
  • Benefits and challenges of pharmaceutical continuous manufacturing
  • Regulatory and market outlook.

About the speaker

Moderator: Clifford Rossi – Professor, University of Maryland

Clifford Rossi is a Professor of the Practice and Executive-in-Residence at the Robert H. Smith School of Business, University of Maryland. Before joining academia, he spent 25‑plus years in the financial sector, as both a C-level risk executive at several top financial institutions and a federal banking regulator. He is the former managing director and CRO of Citigroup’s Consumer Lending Group.

Irina Ramos, PhD – Director, AstraZeneca

Irina Ramos is a director of downstream continuous manufacturing, in the Bioprocess Engineering and Technology group at AstraZeneca in Gaithersburg, MD, USA. She has been a key driver of the technology development and implementation strategy for continuous biomanufacturing. Irina holds a BS/MS in Chemical Engineering from University of Porto (Portugal) and a PhD in Chemical & Biochemical Engineering from University of Maryland, Baltimore County (UMBC).

Sripathy Venkatraman – VP, Head of Global R&D Operations at Curia

Sripathy Venkatraman is Curia’s Vice President and Head of R&D Global Operations. He has over 25 years of experience in the healthcare sector, leading global R&D teams in the development of Drug Substance and Drug Products. He has been with Curia for the past 21 years with the majority of his experience in the small molecule space. Sripathy holds a PhD in Organic Chemistry from the Tulane University and an MBA from University at Albany (SUNY).

Jan-Sebastiaan Uyttersprot – Head of Manufacturing and Powder Technology, UCB

Sebastiaan is leading the Manufacturing & Powder Technologies group, which is accountable for development and manufacture of drug products from preclinical and clinical development and scale-up to the commercial phase, including Process Analytical Technology (PAT) and digital twin development. Before joining UCB (2020), he worked as a data scientist for Indigomed, designing an implantable NIR sensor to monitor metabolites for chronic diseases. Sebastiaan started his career in Procter & Gamble, and during the last 10 years at P&G, he founded the PAT department that developed for all product categories in and atline applications around the globe.